-
1 month ago | 
clinicalleader.com | Miranda McLaren
By Miranda McLarenExplore the transformative potential of community-based research sites in clinical trials, particularly in enhancing patient experiences and fostering diversity. Traditional trial models often struggle to recruit minority populations due to logistical barriers, but community-based approaches significantly improve accessibility and engagement.
-
1 month ago | 
clinicalleader.com | Miranda McLaren
By Miranda McLarenThe obesity drug development landscape is rapidly evolving, driven by the World Health Organization's recognition of obesity as a critical public health problem. With projections indicating over 161.5 million cases in major pharmaceutical markets by 2033, the demand for effective treatments is surging.
-
1 month ago | 
clinicaltrialsarena.com | Miranda McLaren
Global immunization programs have successfully eradicated or controlled many infectious diseases throughout history. However, challenges like antimicrobial resistance, climate change, and the potential threat of biological warfare are continuously reshaping the global health landscape. As these factors evolve, new pathogens or mutated strains of existing ones may emerge.
-
1 month ago | 
clinicaltrialsarena.com | Miranda McLaren
May 2025 – London & Boston – Perceptive eClinical unveils ClinPhone Pro, a next-generation RTSM platform. Built on over 30 years of experience, ClinPhone Pro integrates seamlessly within the clinical technology ecosystem, offering advanced drug supply simulation and rolling forecast capabilities. This enables sponsors and CROs to plan smarter and run more sustainable trials without adding operational burden.
-
1 month ago | 
businessandamerica.com | Miranda McLaren
Europe has witnessed strong growth in orphan drug approvals over the past decade, yet for pharmaceutical innovators, securing market access for these rare disease therapies remains challenging without the right support. Dozens of new orphan medicines are reaching the market each year under the incentives of the EU Orphan Medicinal Products Regulation, which since 2000 has spurred more than 192 orphan drug approvals through 2022.
-
1 month ago | 
pharmaceutical-technology.com | Miranda McLaren
Orphan drug developers face significant difficulties when navigating market access frameworks in Europe. Could greater use of real-world evidence help close the evidence gap? May 13, 2025 Europe has witnessed strong growth in orphan drug approvals over the past decade, yet for pharmaceutical innovators, securing market access for these rare disease therapies remains challenging without the right support.
-
1 month ago | 
clinicaltrialsarena.com | Miranda McLaren
It’s 2025 and it appears that turbulence is now the new normal in clinical trials. From public health emergencies to natural disasters and geopolitical crises, clinical trial teams have dealt with ongoing challenges over the past five years, impacting participant recruitment, disrupting supply chains, and even jeopardizing participant treatment. As a result, trial teams have identified important learnings.
-
1 month ago | 
clinicaltrialsarena.com | Miranda McLaren
Melissa Peirsel is the Manager of IRT Services at Sharp and brings over 13 years of experience in clinical trial operations. Her career began in the United States Air Force, where she specialized in managing electronic technology systems. Today, she leads the successful delivery of IRT solutions from Sharp’s Bethlehem, Pennsylvania office, helping sponsors navigate the complexities of modern trial design with practical, system-driven insights.
-
2 months ago | 
offshore-technology.com | Miranda McLaren
Per- and polyfluoroalkyl substances (PFAS) have been used to create products in just about every industry since the 1950s. Found in everything from carpets and clothing to food packaging, cosmetics, and fire extinguishing foam, the synthetic chemicals are ubiquitous. However, growing sustainability concerns challenge the dominance of PFAS, with some research suggesting that exposure to certain PFAS materials may result in negative health outcomes.
-
2 months ago | 
clinicaltrialsarena.com | Miranda McLaren
When preparing for an upcoming drug development program, leveraging existing knowledge and strategies to streamline the process from concept to market is essential. One effective approach is platform development, which utilizes pre-established formulations, analytical methods, and manufacturing processes. This strategy provides a flexible foundation for multiple products, helping teams build on successful systems.
